Our understanding of, and approach to, pulmonary arterial hypertension has undergone a
paradigm shift in the past decade. Once a condition thought to be dominated by increased …

Vascular endothelial growth factor (VEGF) is a pluripotent growth and permeability factor
that has a broad impact on endothelial cell function. The lung tissue is very rich in this …

Pulmonary arteries of patients with severe pulmonary hypertension (SPH) presenting in an
idiopathic form (primary PH‐PPH) or associated with congenital heart malformations or …

Clinical pulmonary hypertension is characterized by a sustained elevation in pulmonary
arterial pressure. Pulmonary vascular remodeling involves structural changes in the normal …

The pathogenesis of pulmonary hypertension is a complex multifactorial process that
involves the remodeling of pulmonary arteries. This remodeling process encompasses …

Receptor and non-receptor tyrosine kinases are involved in multiple proliferative signalling
pathways. Imatinib, one of the first tyrosine kinase inhibitors (TKIs) to be approved …

Objectives: This study sought to assess the cellular and histologic basis of irreversible
pulmonary hypertension (PHT) in the clinical setting of congenital heart disease (CHD) …

Continuous intravenous administration of the prostacyclin analogue, epoprostenol (IV-PGI2),
has been shown to improve short-and intermediate-term functional capacity …

S100A4/Mts1 confers a metastatic phenotype in tumor cells and may also be related to
resistance to apoptosis and angiogenesis. Approximately 5% of transgenic mice …

Pulmonary hypertension (PH) is a complex, multifactorial disorder divided into five major
subtypes according to pathological, pathophysiological and therapeutic characteristics …